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Available online 7 September 2012Abstract Unexpected induction of arrhythmias in the heart is still one of the major risks of new drugs despite recent
improvements in cardiac safety assays. Here we address this in a novel emerging assay system. Eleven reference compounds
were administrated to spontaneously beating clusters of cardiomyocytes from human pluripotent stem cells (hPSC-CM) and the
responses determined using multi-electrode arrays. Nine showed clear dose-dependence effects on field potential (FP)
duration. Of these, the Ca2+ channel blockers caused profound shortening of action potentials, whereas the classical hERG
blockers, like dofetilide and D,L-sotalol, induced prolongation, as expected.
Unexpectedly, two potent blockers of the slow component of the delayed rectifier potassium current (IKs), HMR1556 and JNJ303,
had only minor effects on the extracellular FP of wild-type hPSC-CM despite evidence of functional IKs channels. These compounds
were therefore re-evaluated under conditions that mimicked reduced “repolarization reserve,” a parameter reflecting the
capacity of cardiomyocytes to repolarize and a strong risk factor for the development of ventricular arrhythmias. Strikingly, in both
pharmacological and genetic models of diminished repolarization reserve, HMR1556 and JNJ03 strongly increased the FP duration.
These profound effects indicate that IKs plays an important role in limiting action potential prolongation when repolarization
reserve is attenuated. The findings have important clinical implications and indicate that enhanced sensitization to
repolarization-prolonging compounds through pharmacotherapy or genetic predisposition should be taken into account when
assessing drug safety.
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Leiden, The Netherlands. Fax: +31 71 526 8289.
E-mail address: stefan.braam@pluriomics.com (S.R. Braam).
1873-5061/$ - see front matter © 2012 Elsevier B.V. All rights reserved.
http://dx.doi.org/10.1016/j.scr.2012.08.007The majority of pre-clinical pharmaceutical research and
development is focused on the discovery of novel small
molecule modulators of biological targets that are prefera-
bly cell type- and/or disease-specific. The decision-making
49Repolarization reserve determines drug responses in hPSC-CMprocess to select early hit-molecules for further develop-
ment towards pre-clinical candidates relies heavily on
specific and predictive assays to distinguish beneficial
(on-target) effects from detrimental side effects.
It was recognized some 15 years ago that drug-induced
block of human Ether-à-go-go Related Gene (hERG) potassium
channel, which conducts the rapid component of the delayed
rectifier potassium current (IKr), can induce ventricular
tachyarrhythmias in the heart known as Torsade de Pointes
(TdP). As a result, electrophysiological assays that measure IKr
block have since then become standard tools for assessing
cardiac hazard (Fermini and Fossa, 2003). Although these
adverse drug effects occur only rarely, the impact can be high,
with some patients undergoing arrhythmias that are lethal and
the drugs responsible being withdrawn from the market. It is
therefore of key interest to assess these risks accurately during
the early stages of drug development.
Regulatory guidelines intended to manage TdP risk through
assessing the extent of hERG block and QT prolongation both
pre-clinically (ICH S7B) and clinically (ICH E14), turned out
to have several shortcomings. For example, not only QT-
prolonging drugs but also QT-shortening drugs can have
pro-arrhythmic effects (Shah, 2010). In addition, hERG block
alone does not capture all compounds that can induce delayed
repolarization and TdP (Lu et al., 2008b).
These issues can be explained by the fact that repolar-
ization of the cardiac action potential is not only dependent
on IKr, but also depends on other potassium currents,
including the slow component of the delayed rectifier
potassium current, IKs (Li et al., 1996). This is exemplified
by the fact that mutations in KCNQ1, the gene that encodes
for the channel conducting IKs, can cause the pro-arrhythmic
long QT syndrome type 1 (LQTS1) (Moss et al., 2007; Roden
and Viswanathan, 2005).
Although IKs by itself does not have a major effect on the
action potential duration (APD) or QT interval under
base-line conditions (Jost et al., 2005; Lengyel et al.,
2001; Varró et al., 2000; Volders et al., 2003), accumulating
evidence indicates that IKs blocking drugs can be highly
torsadogenic (Guérard et al., 2008; Towart et al., 2009).
This can be explained by the concept of “repolarization
reserve” (Varro and Baczkó, 2011). The idea of repolariza-
tion reserve is that the complexity of repolarization,
that returns the action potential to its resting state, includes
some redundancy. Reduction of one component (such as IKs)
ordinarily will not lead to failure of repolarization
(i.e. marked action potential prolongation) but individuals
with lesions in other components of the system, say IKr, may
be sensitized and react strongly (Roden, 1998, 2008).
However, IKs function in human cardiac repolarization is
still incompletely understood. It is therefore of significant
concern that there are several drugs on the market, or in
development, which block IKs in addition to IKr and/or INa.
Examples of such drugs include the diuretic indapamide
(Letsas et al., 2006), the class III anti-arrhythmic azimilide
(Davies et al., 1996) (Carlson, 2005) and the anti-arrhythmic
vernakalant (Camm and Savelieva, 2008). Furthermore, in
addition to direct interaction with outward repolarization
currents, compounds can also delay repolarization through
other mechanisms. For example, an increase in peak and
late sodium current (Lacerda et al., 2008) or in calcium
currents can also prolong the action potential/QT interval(Lu et al., 2008a). Taken together, it is clear that the less
frequent effects on other ion channels are much more
complex and difficult to capture than hERG risks.
Thus there is a clear unmet need to evaluate cardiac
responses of candidate compounds in a model with higher
predictability, which recapitulates the complex ion-channel
interactions of cardiomyocytes in the human heart as closely
as possible. Such a model could be used early in compound
development as a better tool for hazard identification, for
assessing structure activity relationships with the cardiac
side effects, and for secondary screening or possibly full
risk-assessment.
As previously shown, hPSC-CM have the potential to
become a useful cardiac model during pre-clinical R&D
(Braam et al., 2010). Here, we have used the same assay,
based on microelectrode arrays (MEAs), to provide evidence
that hPSC-CM can reliably detect hERG or calcium blocking
properties among a more diverse set of compounds than
previously reported, and that the safety profiles that
emerge are comparable with those using current assays
based on primary cardiomyocytes. More importantly, we
showed that we are able to detect more complex genetic
and compound interactions on the basis of hPSC-CM.
Specifically, we tested the concept that reduced repolari-
zation reserve could affect sensitivity to IKs block. We
showed that (i) pharmacological inhibition of IKr and (ii)
genetic inhibition caused by a mutation in hERG in patients
with LQTS2, from whom we generated induced pluripotent
stem cells (hiPSC) then derived cardiomyocytes, predisposed
to enhanced sensitivity to IKs block. This clearly demonstrat-
ed the relevance of this approach to personalized medicine
in clinical practice and illustrated the high utility of hPSC
technology in predicting compound effects on human hearts.
Materials and methods
Cell culture and differentiation
Envy cells (Costa et al., 2005) and LQTS2-hiPS cells (Matsa et
al., 2011) were routinely cultured on 129SV Mouse embry-
onic fibroblasts (MEFs) to maintain pluripotency and induced
to differentiate on END-2 cells as described previously
(Mummery et al., 2003; Passier et al., 2005). Contracting
areas are obtained within 12 days that consist routinely of
20–25% cardiomyocytes and 75–80% endodermal or other
mesodermal derivatives. On day 12 co-cultures were
maintained in low serum medium (5%). Beating areas were
microdissected (MEA) or dissociated (patch clamp) and
replated at day 20.
Patch clamp electrophysiology
Recordings were performed on single cardiomyocytes, identi-
fied on the basis of their typical morphology. Data were
collected from 2 independent differentiations and shown as
mean±SEM (differences between differentiations have not
been observed). Potassium currents were measured in the
whole-cell configuration of the patch-clamp technique with
the use of an Axopatch 200B amplifier (Molecular Devices).
Patch pipette had a tip resistance of ~2 MΩ and series
resistance was compensated by ≥80%. Currents were filtered
50 S.R. Braam et al.at 1 kHz and digitized 2 kHz. Potentials were corrected for the
estimated liquid junction potential (+17 mV). Voltage con-
trol, data acquisition, and analysis were performed with
pClamp10.1/Clampfit (Axon Instruments).
Potassium currents were recorded at 37 °C using an
internal solution containing (mM): K-gluconate 125, KCl 20,
K2-ATP 5, HEPES 10, EGTA 10, pH 7.2 (KOH). The external
solution contained the following (mM): NaCl 140, KCl 5.4,
CaCl2 1.8, MgCl2 1.0, glucose 5.5, HEPES 5, nifedipine 0.005,
pH 7.4 (NaOH).
Currents were elicited using 5 s depolarizing pulses from a
holding potential of −40 mV, as indicated in the voltage
protocols depicted in Fig. 2. IKs was measured as a 500 nM
JNJ303-sensitive current, while IKr was measured as a 1 μM
E-4031-sensitive current in the presence of 500 nM JNJ303.
After performing the subtraction traces, values at the end of
the 5 s depolarizing step were plotted against the voltage.
These values correspond to themaximumdifferences between
the traces. Current densities were calculated by dividing
current amplitude (pA) by cell membrane capacitance (pF).
MEA electrophysiology
MEA chips were plasma cleaned and coated with fibronectin for
1 hour at 37.0 °C. Clumps (~200–300 μM) of beating hESC-CM
clusters were micro dissected using surgical scissors and
positioned on the electrodes of standard 60 electrode MEAs or
alternatively 6-well MEAs. Extracellular recording was per-
formed after cell attachment using aMEA1060INVMEA amplifier
(Multi Channel Systems, Reutlingen, Germany). Output signals
were digitized at 10 kHz by use of a PC equippedwith a MC-card
data acquisition board (Multi Channel Systems, Reutlingen,
Germany). Standard measurements were performed in DMEM
culture medium supplemented with 5% FCS. During recording,
the temperature was maintained at 37.0 °C. Data were
recorded using QT-screen (Multi Channel Systems, Reutlingen,
Germany) and analyzed off-line with QT-analyzer (Multi
Channel Systems, Reutlingen, Germany) and statistically
analyzed using GraphPad Prism. Data are presented as mean±
SEM.
Test compounds terfenadine, sparfloxacin, moxifloxacin,
diltiazem, verapamil, bepridil, Levcromakalim, JnJ303,Table 1 The effect of various compounds on field potentials of
Compound class Name
hERG block Dofetilide
hERG block D,L-sotalol
hERG block Terfenadine
hERG block Sparfloxacin
hERG block Moxifloxacin
Calcium blocker Diltiazem
Calcium blocker Verapamil
Non selective Calcium/hERG
blocker
Bepridil
ATP sens. K+ channel activator Levcromakalim
IKs blocker JNJ303
IKs blocker HMR1556HMR1556, Dofetilide en D,L-sotalol were dissolved in DMSO
at 10 mM and serial dilutions were made in culture medium.
The highest concentration of DMSO was reached at 30 μM
drug which represents 0.3% DMSO. Measurements were
started after a wash-in time of 2 min.Results
hPSC-CM drug responses
In a previous study, we developed a MEA-based screening
platform to measure the electrophysiological responses of
human embryonic stem cell derived cardiomyocytes
(hESC-CM) to well-characterized drugs (Braam et al.,
2010). Concentration response curves demonstrated that
the assay predicted the effects of drugs, at clinically
relevant concentrations, as accurately as already reported
for the human heart. This included block of the hERG ion
channel, which is the main cause of drug-induced QT
prolongation. To validate this model for predictive cardiac
safety pharmacology further, we initiated a new study
(blinded to the operator) based on a test set of reference
compounds with blocking or activating effects on various ion
channels (Table 1, Fig. 1 and Supplemental Fig. 1).
From this screen it was clear that the effects of the hERG
blockers dofetilide, dl-sotalol, terfenadine, sparfloxacin and
moxifloxacin could be reliably detected by measuring FP
prolongation. Similarly, the calcium blockers diltiazem and
verapamil and the ATP sensitive potassium activator
levcromakalin could be detected by measuring the shorten-
ing of the FP duration. Verapamil is of special interest since
it exerts its action by blocking L-type calcium channels but is
also a potent hERG blocker. Nevertheless, since the calcium
channel blocking effects are dominant over the hERG
blocking effects, the net result is FP shortening.
However, despite the convincing results with the ATP-
sensitive potassium activator levcromakalin and the 5 hERG
blockers, we observed little effect of blocking the other
major repolarizing current, the slow component of the
delayed rectifier potassium current (IKs) (Fig. 1). Both IKs
blocking compounds, JNJ303 (Towart et al., 2009) andhPSC-CM.
Predicted effect on
repolarization
Response
hPSC-CM
Number of
observations
FP prolong. Observed 3
FP prolong. Observed 4
FP prolong. Observed 3
FP prolong. Observed 4
FP prolong. Observed 3
FP short. Observed 2
FP short. Observed 4
FP prolong. Observed 8
FP short. Observed 8
– – 3
– – 3
Fig. 1 The effect of potassium channel blocking compounds on cardiac repolarization. FP–duration dose relationship for hPSC-CM
in the presence of increasing amounts of (A) dofetilide (B) D,L-sotalol (C) JNJ303 and (D) HMR1556. The arrows indicate the
concentration which prolonged the FP-duration by approximately 20%.
51Repolarization reserve determines drug responses in hPSC-CMHMR-1556 (Thomas et al., 2003) are considered potent
blockers with IKs IC50 of 0.064 and 0.011 μM respectively.
Although the role of IKs in human cardiac repolarization is
not completely understood, it has been firmly established
that mutations in KCNQ1 are associated with the occurrenceFig. 2 Characterization of the slow (IKs) and rapid (IKr) compo
Representative examples of current traces elicited upon a depolari
presence of 500 nM JNJ 303 (A) and in the combined presence of 500
current (C) and IKr, defined as E4031-sensitive current (D) were
application of JNJ 303 and E4031, respectively. Fig. E and F show av
voltage protocols.of LQTS1 and TdP. Previously it has been shown that in the
absence of sympathetic stimulation, IKs plays little role in
normal human ventricular muscle repolarization (Jost et al.,
2005). In addition, several investigators reported that
neither JNJ303 nor HMR1556 had much effect on APD innent of the delayed rectifier potassium current in hPSC-CM.
zing step from −40 mV to −20 mV, in control conditions, in the
nM JNJ 303 and 1 μM E-4031 (B). IKs, defined as JNJ 303-sensitive
obtained by subtraction of the current before and after the
erage current–voltage relationships for IKs (E) and IKr (F). Insets:
Fig. 3 Pharmacological models for an attenuated repolarization response. hPSC-CM were treated with 10 μM D,L-sotalol (A) or
30 nM dofetilide (D) respectively, both compounds prolonged the field potential by approximately 20%. In each individual experiment
the field potential duration was re-normalized to 100% after D,L-sotalol or dofetilide administration. Subsequently FP–concentration
response curves were made for the IKs blockers JNJ303 (B,E) and HMR1556 (C,F). Please note differences in y-axes (B,C,E,F).
52 S.R. Braam et al.isolated rabbit and dog cardiac tissues in vitro, whereas they
evoked unprovoked TdP in vivo in anaesthetized dogs
(Towart et al., 2009; Volders et al., 2003) (see supplemental
Table 1 for compound characteristics). We therefore carried
out follow up studies to elucidate the role of IKs in hPSC-CM.
Presence of IKs and IKr currents in hPSC-CM
Having established that both JNJ303 and HMR1556 had minor
effects on the repolarization of spontaneously beating
hPSC-CM (Fig. 1) we reasoned that this could likely be
explained in two possible ways: 1) The potassium channel
responsible for the IKs current is not present or is not
functional, or, 2) IKs has a contribution to the repolarization
of hPSC-CM under specific conditions, essentially in line with
previous observations in adult human cardiomyocytes.
To determine whether IKs and IKr currents were present in
hESC-CMs we first examined their electrophysiological prop-
erties with the specific reference compounds E4031 (for IKr)
and JNJ303 (for IKs) using the whole-cell configuration of the
patch-clamp technique. Representative examples of cur-
rent traces elicited upon a depolarizing step from −40 mV
to −20 mV, in control conditions, in the presence of JNJ 303,
and in the combined presence of JNJ 303 and E-4031 are shown
in Fig. 2A and B. IKs, defined as JNJ 303-sensitive current
(Fig. 2C) and IKr, defined as E4031-sensitive current (Fig. 2D),were determined by subtracting the currents before and after
the application of JNJ 303 and E4031, respectively.
Average current–voltage (I–V) relations for IKs and IKr
(Fig. 2E and F), were obtained by plotting the currents
measured at the end of the depolarizing steps against
the voltage. In line with previous findings in animal
models (Towart et al., 2009), and adult human ventricular
cardiomyocytes (Li et al., 1996) both channels open around
−50 mV, IKs increases towards more positive potentials,
whilst IKr, decreases in accordance with its inward
rectification.
IKs blocking drugs in a pharmacological model of a
diminished repolarization reserve
Since IKs and IKr were both present on hPSC-CM, we
hypothesized that IKs is primarily involved in restricting
excessive action potential duration. We therefore tested the
effect of the IKs blockers in a pharmacological model of
attenuated repolarization reserve. For this, we used the
clinically well-characterized hERG blocking drugs dofetilide
and D,L-sotalol at 30 nM and 10 μM respectively. These
concentrations were chosen because they prolonged the FP
by ~20% in previous experiments (Fig. 1). We started the
experiments with a baseline recording followed by a second
recording after addition of D,L-sotalol or dofetilide (Fig. 3A
Fig. 4 The effect of IKs blockers in LQTS2 cardiomyocytes. FP
duration dose relationship for the IKs blockers JNJ303 and
HMR1556 in LQTS2 hPSC-CM (black lines). For comparison
purposes data from the control cardiomyocytes (Fig. 1C and D)
is plotted in gray. Significance is calculated using a 2-way
repetitive ANOVA test and indicated with an asterisk.
53Repolarization reserve determines drug responses in hPSC-CMand D). Consistent with previous experiments, we observed a
~20% prolongation of cardiac repolarization.
Next, the FP duration was re-adjusted to 100% and JNJ303
(Fig. 3B and E) or HMR1556 (Fig. 3C and F) were titrated in.
Strikingly, sotalol administration sensitized the cells consid-
erably which resulted in an additional maximum prolongation
of ~25% with JNJ303 and ~50% with HMR1556. Similarly, using
dofetilide as a compound to reduce the repolarization
response, we observed an additional 80% field potential
prolongation with JNJ303 and ~150% with HMR1556. In
summary, pharmacologic block of IKr prolonged the action
potential but also sensitized the cells to IKs blockers. Although
IKs block had little effect on wildtype cells, cells challenged
with IKr blockers showed a striking delay in repolarization
when exposed to IKs blockers. It is unlikely that this is caused
by drug-drug interactions since we observed similar phenom-
ena with the four IKr/IKs compound combinations.
IKs blocking drugs in a genetic LQTS2 cell model
To investigate the possible clinical relevance of these
findings further, we determined the response of IKs blocking
drugs in a genetic model of a diminished repolarization
reserve. We used a patient-derived hiPSC line for this, which
has previously been described as a model for LQTS2 (KCNH2
G1681A) (Matsa et al., 2011) Without further intervention
under normal conditions, cardiomyocytes from this hiPSC
line had already shown a reduction in IKr compared to
cardiomyocytes from normal control hiPSC (Matsa et al.,
2011). As in the pharmacological model of reduced repolar-
ization reserve, we also observed in this genetic model a
maximum 30% prolongation with JNJ303, which is signifi-
cantly more (pb0.05 2-way repeated measures ANOVA) than
that in the control hPSC-CM (Fig. 4a). Using HMR1556 we
observed a similar outcome: control hPSC-CM again showed
little response, whilst the LQTS2-CM showed significantly
stronger prolongation (pb0.05 2-way repeated measures
ANOVA) of approximately 25% (Fig. 4b).
Discussion
For implementation of stem cell technologies in pre-clinical
drug development, robust methods for reproducible, efficient
and high yield differentiation of hPSC to cardiomyocytes are of
critical importance. Preferably these cardiomyocytes would
also resemble adult human cardiomyocytes. Previously, we
developed a MEA-based assay with view to cardiac safety
pharmacology application, which relied on the analyses of
extracellular field potentials from hESC-CM. We showed
dose-dependent responses for 12 cardiac and non-cardiac
drugs, at concentrations that closely overlapped with drug
serum levels in patients. Here,we used this assay again but in an
unbiased, blinded screen of a panel of compounds with known
effects on cardiac ion channels. We thus obtained additional
evidence that hPSC-CM can be used to detect compounds with
various effects on cardiac repolarization with a high predictive
value. In addition, we performed the first detailed analyses of
IKs function in hPSC-CM and tested the concept of repolarization
reserve in a human experimental model system. To do this, we
used a pharmacological approach, which relied on combinations
of specific IKr and IKs blocking compounds. These experimentssuggested that hPSC-CM repolarize, just like canine and human
ventricular cardiomyocytes, with a strong safety margin
(‘repolarization reserve') (Biliczki et al., 2002; Jost et al.,
2005; Varro and Baczkó, 2011; Volders et al., 2003). However,
when this normal repolarization reserve is attenuated (for
example due to a reduction of IKr), minimal or moderate
potassium current inhibition is now sufficient to result in
excessive prolongation of the action potential. To investigate
whether other causes of reduced repolarization reserve might
impact the outcome of drug responses, we took advantage of a
previously established LQTS2 hiPS cell line and showed for the
first time the effect of IKs blockers on LQTS2 cardiomyocytes.
From these studies we concluded that our hPSC-CM assay
complements and faithfully recapitulates data from adult
human ventricular cardiomyocytes. This is an essential step
towards further implementation of hPSC-CM for pre-clinical
cardiac safety pharmacology.
The stem cell based cardiomyocyteMEA assay, as described
here, has important advantages over more traditional models
for pre-clinical safety pharmacology hazard identification.
The present “gold standard” first line test to assess cardiac
safety of a new chemical entity is a hERG binding assay or
patch clamp electrophysiology to determine the IC50 value for
hERG. Generally, this relies on artificial over-expression of the
relevant functional ion channel in non-cardiac cell lines such
as HEK293, which over-simplify a complex process that is
state-, time- and voltage-dependent. In addition, the chan-
nels are usually over-expressed as homomeric alpha subunits
rather than the physiologically more relevant hetero-
oligomeric channel complexes, and in the absence of other
cardiac ion channels and interacting proteins, which has
54 S.R. Braam et al.important functional consequences. For example, in native
cardiomyocytes, the α-subunits hERG and KvLQT1 form a
complex with their respective β-subunits MiRP1 and Mink.
Furthermore there is biochemical evidence of molecular
interactions between hERG and KvLQT1 can interact with,
modify the localization, and increase the current-carrying
properties of hERG (Biliczki et al., 2009). Next to the
functional interaction of the pore forming proteins with the
β-subunits, there is evidence that these ion channels also
require complex interactions with several other proteins
(ABBOTT et al., 2007). For example, the IKs macromolecular
complex contains the A-kinase-anchoring protein Yotaio, and
the phosphodiesterase PDE4D3 (Terrenoire et al., 2009).
Further biological evidence for the relevance of these findings
comes from a recent study that described major differences in
hERG channel function whether they were expressed in HEK293
or neonatal rat cardiomyocytes (Lin et al., 2010).
Like many of the established animal based ex vivo cardiac
safety pharmacology models (Langendorf, Purkinje fiber,
ventricular wedge) the present assay is based on measuring
the net cellular electrical activity (monophasic action
potential or field potential in case of the MEA) instead of a
single isolated current. The action potential relies on the
interaction and relative contribution of many ion channels,
which is subject to considerable species differences
(Nerbonne and Kass, 2005; Terrar et al., 2006). Therefore
it is of interest to work with human cells.
Taking the full property spectrum of cardiomyocytes into
account is an obvious advantage; however it also results in an
additional complexity. Some compounds might show no effect
because the net effect on cardiac repolarization is zero (for
example in case of dual calcium and hERG block) while others
might show variable effects due tomulti-channel block. The last
point is illustrated by increasing variability in the micro-molar
range of most compounds. One-way ANOVA and Bonferroni's
multiple comparison post-tests indicate that the 30 μM
data-point gives significant more variation than the three
lowest concentrations in the single drug experiments (pb0,05).
Finally, some compound effects may be masked by the
functionality of other ion channels. An example of this was our
failure to find major effects with IKs blocking drugs. However a
simple challenge with either D,L-sotalol or dofetilide reduced
the repolarization reserve and exposed the effects of IKs
blockers. Interestingly, we observed that although all combina-
tions of IKr and IKs blockers and IKs blockers on LQTS2 cells yield
similar results, it is evident that the pharmacological experi-
ments with dofetelide and IKs blockers yield more pronounced
FPD prolongations compared either D,L-sotalol and IKs block or
LQTS2 cells and IKs block. The concentration of D,L-sotalol used
in these experiments is in the estimated therapeutic plasma
concentration unbound range (ETPCunbound) (Supplemental
Table 2) while the concentration of Dofetelide used in this
experiment is approximately 15× higher than the
ETPCunbound. This might explain the difference between D,
L-sotalol and dofetelide in Fig. 3. Since the ETPCunbound will
not be known early in compound development it is of interest to
profile unknown compounds under various controlled conditions
(e.g. in spontaneously beating control cells and in conditions
mimicking reduced repolarization reserve). Traditional patch
clamp electrophysiology techniques may subsequently be used
if the stem cell based field potential duration assay suggests
unwanted side effects on cardiac repolarization. Eventuallystructure activity relationships may then be used to develop
analogues with reduced side effects.Clinical implications
Mutations in the IKs potassium channel are associated with
LQTS1, yet our findings in control hPSC-CM indicated that
pharmacological IKs block had only minor effects on the
action potential duration. Although our findings are in line
with those previously obtained with normal human ventric-
ular tissue (Jost et al., 2005) they remained difficult to
reconcile. One important aspect is that the clinical pene-
trance of LQTS mutations is rather low (Priori et al., 1999).
This means that not all individuals with the LQTS genotype
display the associated clinical phenotype.
However, in both a pharmacological and genetic model of
diminished repolarization reserve, we showed striking effects of
IKs blockers on the FP duration. Our results therefore suggest
that individuals with a reduced repolarization reserve lack the
ability to compensate and limit excessive APD lengtheningwhen
exposed to IKs blocking compounds. This is in particular a serious
safety issue in (cardiovascular) patients, who are in some cases
already being treatedwith potent IKr blocking compounds like D,
L-sotalol or dofetilide. However, it is important to realize that it
is believed that the repolarization reserve of individuals can be
diminished by “more general phenomena” such as extreme
bradycardia, hypothyroidism, hypokalemia, changes in auto-
nomic neural influences, or exposure to drugs affecting other
repolarizing currents (e.g., ICa, Ito, IK1) (Lacerda et al., 2008;
Roden, 2008; Varro and Baczkó, 2011).
In addition to individuals with an acquired reduction in
the repolarization reserve, another group of patients at risk
are those suffering from one of the inherited long QT
syndromes, in particular LQTS1 and LQTS2. Most of these
patients suffer from mutations in IKr or IKs and there is strong
clinical evidence showing that these patients are very
sensitive to repolarization-affecting drugs (Obeyesekere
et al., 2011). Finally, IKs blocking compounds may expose a
(genetic) subclinical repolarization defect in otherwise
healthy patients. Indeed, the IKs blocker indapamide
(which also blocks IKr and other cardiac ion channels) has
been reported as having caused TdP in at least one human
subject. Evidence for the hypothesis that drugs may expose
sub-clinical repolarization defects in patients comes from a
clinical study (Kaab et al., 2003). The authors reported that
patients who previously experienced drug induced TdP
developed excessive QTc prolongation after sotalol treat-
ment, compared to the control group consisting of patients
without history of TdP. Interestingly QTc duration in both
groups were similar at baseline, suggesting that the striking
differences in response to the administered drug were due to
differences in the repolarization reserve.
In conclusion, our results demonstrate that (1) assays
based on wild-type and “diseased” hPSC-CM complement or
could potentially replace some of the preclinical cardiac
toxicity screening tests currently used in the pre-clinical
development of novel chemical entities, particularly in early
developmental phases when improved decision making and
cost reduction would have high impact; (2) IKs plays an
increasingly important role in limiting action potential
prolongation when cardiac muscle repolarization reserve is
55Repolarization reserve determines drug responses in hPSC-CMreduced, either pharmacologically, or congenitally; (3)
compounds selected for further development should also
be examined for IKs liability before subsequent tests in
humans; (4) patients with an attenuated repolarization
reserve, in particular LQTS2 patients, are at risk of
developing excessive QT prolongation and potentially TdP
when exposed to blocking drugs. The assay described here is
capable of detecting this increased risk.
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